This analysis examines the historical and forecast performance for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Eli Lilly’s performance against key rivals in the ethical pharmaceutical sector
Analyze Lilly’s prospects of overcoming the decline of its key historical growth driver, Zyprexa
See how Cymbalta’s ongoing growth will be critical to the company’s performance.
